Clinical Trials
4 trialsNCT04800822 2026-06-04
PF-07284892 in Participants With Advanced Solid Tumors
Pfizer
Phase 1 Terminated
NCT07617337 2026-06-01
AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer
Chugai Pharmaceutical
Phase 1 Not yet recruiting
NCT07556549 2026-05-22
A Study to Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese Adults With ALK-positive a/mNSCLC
Pfizer
Active not recruiting
NCT05297890 2026-05-19
A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer
CStone Pharmaceuticals
Phase 2 Active not recruiting